Together, we highlight that PPM1A may represent a therapeutic target for metabolic diseases in many aspects, such as increasing anti-inflammatory responses and enhancing the secretion of insulin-sensitizing adipokines which depends on dephosphorylation of PPARγ at Ser273. This evidence concerns the gene INS and metabolic disease.